Private financings for life‑science tools and diagnostics fell 20% year‑over‑year in H2 2025, according to GenomeWeb/360Dx data, with total investment of $1.21 billion across 38 transactions. The sector felt pressure from tariffs, federal funding uncertainty and subdued pharma R&D spend; average deal size edged up slightly but total rounds and aggregate capital declined. Daily financing round trackers published Dec. 30 capture ongoing capital activity and highlight smaller raises that persisted despite the pullback. The financing slowdown could delay commercialization timelines for some instrumentation and diagnostics startups and compress valuation multiples for deals in 2026.